← Back to Screener
Disc Medicine, Inc. Common Stock (IRON)
Price$71.41
Favorite Metrics
Price vs S&P 500 (26W)-6.07%
Price vs S&P 500 (4W)13.89%
Market Capitalization$2.74B
All Metrics
Book Value / Share (Quarterly)$19.53
P/TBV (Annual)7.35x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.79
Price vs S&P 500 (YTD)-13.76%
EPS (TTM)$-5.98
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-5.98
EPS (Annual)$-6.01
ROI (Annual)-23.17%
Cash / Share (Quarterly)$20.88
ROA (Last FY)-22.00%
EBITD / Share (TTM)$-6.68
ROE (5Y Avg)-26.32%
Cash Flow / Share (Annual)$-3.15
P/B Ratio3.70x
P/B Ratio (Quarterly)4.05x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-32.58x
ROA (TTM)-30.19%
EPS Incl Extra (Annual)$-6.01
Current Ratio (Annual)21.48x
Quick Ratio (Quarterly)21.59x
3-Month Avg Trading Volume0.66M
52-Week Price Return75.05%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$14.87
52-Week High$99.50
EPS Excl Extra (Annual)$-6.01
26-Week Price Return2.68%
Quick Ratio (Annual)21.32x
13-Week Price Return-6.89%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)21.94x
Enterprise Value$2,676.762
Revenue / Employee (Annual)$0
Cash / Share (Annual)$16.33
3-Month Return Std Dev73.13%
Net Income / Employee (TTM)$-1
ROE (Last FY)-24.63%
Net Interest Coverage (Annual)-188.03x
EPS Basic Excl Extra (Annual)$-6.01
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-5.98
ROI (TTM)-31.40%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$10.15
Price vs S&P 500 (52W)39.95%
Year-to-Date Return-9.62%
5-Day Price Return4.83%
EPS Normalized (Annual)$-6.01
ROA (5Y Avg)-23.60%
Month-to-Date Return12.25%
Cash Flow / Share (TTM)$-3.60
EBITD / Share (Annual)$-6.68
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-25.55%
LT Debt / Equity (Quarterly)0.04x
EPS Basic Excl Extra (TTM)$-5.98
P/TBV (Quarterly)3.62x
P/B Ratio (Annual)4.25x
Book Value / Share (Annual)$14.80
Price vs S&P 500 (13W)-9.75%
Beta1.01x
Revenue / Share (TTM)$0.00
ROE (TTM)-32.80%
52-Week Low$39.20
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.32
4.32
4.32
4.32
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IRONDisc Medicine, Inc. Common Stock | — | — | — | — | $71.41 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic disorders through modulation of heme biosynthesis and iron homeostasis. The company's pipeline includes bitopertin for erythropoietic porphyrias, DISC-0974 for anemia in myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera. These programs target conditions with significant unmet medical needs and substantial market opportunities.